Clinical Trials solutions 

Precision Enrollment

Meet your recruitment targets & deadlines by granting treatment access to fully characterised patients

Scroll down to discover

Our Approach

Many targeted clinical trials are not solely related to gene alterations but are depending on the expression of a specific protein, the presence of a novel mRNA transcript, the occurrence of a methylation event or the expression of a checkpoint inhibitor biomarker.

Hence, the best treatment options cannot be established by relying merely on DNA analysis. OncoDNA characterizes patients by NGS and searches for specific SNVs, CNVs, Indels and translocations but is also relying on molecular pathology tools for monitoring the expression of specific receptors or biomarkers using IHC and by assessing methylation status.

This approach offers the highest chances to find a match between a patient looking for an effective treatment and a biopharma company recruiting patients for their trial.

CONTACT US

Meet your recruitment targets & deadlines by granting treatment access to fuly characterized patients

 

More and more oncology clinical trials do not meet enrollment deadlines and they sometime do fail to meet recruitment targets. Increase in the number of clinical trials, increase in the complexity of the patient to be recruited make that patient enrollment has become a cucial aspect of clinical trials in oncology. Thanks to its extensive oncology network and patient testing services, OncoDNA can bring together those patients searching access to treatment and the recruiting clinical trials.

Your benefits?

They already put their trust in our expertise

Interested knowing why? 
Go to testimonials
M.D. Ph.D Antonio Gualberto
Head of Development and Chief Medical Officer
Kura Oncology - USA

"Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions"

Dr. Alan L. HO
Oncologist
Memorial Sloan Kettering Cancer Center - USA

The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)